Lifirafenib

DB14773InvestigationalSmall molecule

Lifirafenib is under investigation in clinical trial NCT03641586 (The Study of BGB-283 in Chinese Subjects With Local Advanced or Metastatic Malignant Solid Tumor).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase B-raf
Curator reviewed
Formula / weight: C₂₅H₁₇F₃N₄O₃ · 478.431 g/mol (avg)
Code names: BGB-283

Resolves to

Compound

UNII8762XZS5ZFCAS1446090-79-4

Structure

InChIKeyNGFFVZQXSRKHBM-FKBYEOEOSA-NSMILESFC(F)(F)C1=CC2=C(C=C1)N=C(N2)[C@@H]1[C@H]2OC3=C(C=C(OC4=C5CCC(=O)NC5=NC=C4)C=C3)[C@@H]12

Targets

P15056BRAF

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lifirafenib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account